Nijsten MW, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro[J]. Crit Care Med, 2000, 28(2): 458-461.
[3]
Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin-in fluence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentration[J]. Eur J Clin Chem Clin Biochem, 1997, 35(8): 597-601.
[4]
Claude L, Philippe C, Olivier G, et al. Mass tuansfer,clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure[J]. Critical Care, 2003, 6(7): 160-165.
[5]
Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection[J]. Lancet, 1993, 341(8844): 515-518.
[6]
Phua J, Koay ES, Lee KH. Lactate procalcitonin and am ino-teminalpro B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock[J]. Shock, 2008, 29(3): 328-333.
[7]
Ghorbani G. Procalcitonin role in differetial diagnosis of infection stages and non-infection inflammation[J]. Pak J Biol Sci, 2009, 12(4): 393-396.
[8]
Masia M, Gutiarez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index[J]. Chest, 2005, 128(4): 2223-2229.
[9]
Ruokonen E, Nousiainen T, Pulkki K, et al. Procalcitonin concentration in patients with neutropenic fever[J]. Eur J Clin Microbiol Infect Dis, 1999, 18(4): 283-285.
[10]
Giamarelbs-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia[J]. Clin Infect Dis, 2001, 32(12): 1718-1725.
[11]
Engel A, Steinbach G, Kern P, et al. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8[J]. Scand J Infect Dis, 1999, 31(2): 185-189.
[12]
Kang YA, Kwon SY, Yoon HI, et al. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia[J]. Korean J Intem Med, 2009, 24(4): 337-342.
[13]
Cvan Rossum AM,Wulkan RW,Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children[J]. Lancet Infect Dis, 2004, 4(10): 620-630.
[14]
Chiwakata CB, Maneqold C, Bonicke, et al. Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria[J]. J Infect Dis, 2001, 183(7): 1161-1164.
[15]
Alnawas B, Shah P. Procalcitonin in acute malaria[J]. Eur J Med Res, 1997, 2(5): 206-208.
[16]
Levy MM, Fink MP, Marshall JC, et al. 2001 Scm/ESKM/ACCP/ATS/SIS international sepsis definitions conference[J]. Crit Care Med, 2003, 31(4): 1250-1256.
[17]
Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:cluster-randomised, single-blimded intervevtion trial[J]. Lancet, 2004, 363(9409): 600-607.
[18]
Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-accquired pneumonia: a randomized trial[J]. Am J Respir Crit Care Med, 2006, 174(1): 84-93.
[19]
Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy[J]. Chest, 2007, 131(1): 9-19.
[20]
Briel M, Christ-Crain M,Young J, et al. Procalcitonin-guided antibiotic use verse a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised trail and baseline characteristics of participating general practitioners[J]. BMC Fam Pract, 2005, 6(8): 34.
[21]
Marc E, Menager C, Moulin F, et al. Procalcitonin and viral meningitis:reduction of unnecessary antibiotics by measurement during an outbreak[J]. Arch Pediatr, 2002, 9(4): 358-364.
[22]
Hillas G, Vassilakopoulos T, Plantaz P, et al. CRP and PCT as predictors of survival and septic shock in ventilator-asssociated pneumonia[J]. Eur Pespir J, 2010, 35(4): 805-811.
[23]
Tang H, Huang T, Jing J, et al. Effect of Procalcitonin-guided treatment in patients with infections a system review and mete-analysis[J]. Infection, 2009, 37(6): 497-507.
[24]
Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of sever community-accquired pneumonia[J]. Intensive Care Med, 2006, 32(3): 469-472.
[25]
Giamarelbs-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnosis marker of underlying infection in patients with febrile neutropenia[J]. Clin Infect Dis, 2001, 32(12): 1718-1725.
[26]
Fleischhack G, Kambeck I, Cipic, D, et al. Procalcitonin in paediatri cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumor necrosis factor receptor II[J]. Br J Haematol, 2000, 111(4): 1093-1102.
[27]
Ostermann H, Kratz-Alliers K, Mesters RM, et al. Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocycopenic patients[J]. Infect Dis, 1997, 176(3): 825-828.
[28]
Spittler A, Razenberger M, Kupper H, et al. Relationship between interleukin-6 plasma concentration in patients with sepsis monocyte phenotype, monoeyte phagocytic properties, and cytokine production[J]. Clin Infect Dis, 2000, 31(6): 1338-1420.
[29]
Darrlas P, Ledoux D, Nys M, et al. Cytokine serum level during sew′re sepsis in human IL-6 as a marker of severity[J]. Ann Surg, 1992, 215(4): 356-362.
[30]
deBont ESJM, Vellenga E, Swaanenburg JCJM, et al. Plasma IL-8 and IL-6 level can be used to define a group with lower risk of septicaemia among cancer patients with fever and neutropenia[J]. Brit J Hoemotol, 1999, 107(2): 375-380.
[31]
Lehrnbecher T, Venzon D, de Haas M, et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein,soluble Fc gamma receptor type Ⅲ, and mannose-binding protein in febrile children with cancer and neutropenia[J]. Clin Infect Dis, 1999, 29(2): 414-419.
[32]
Kuo TH, Chuang SC, Chang SY, et al. Ligand specificities and structual requirement of two Tachypleus plasma lectins for bacterial trapping[J]. Biochem J, 2006, 393(3): 757-766.
[33]
Nahid AM, Suggi S.Binding of porcing ficolin-alpha to lipopolysaccharides from Gram-negtive bacteri and lipoteichoic acids from Gram-positive bacteria[J]. Burns, 2001, 27(2): 145-149.
[34]
Jacobs MR, Good CE. Relationship betwween bacterial load′species virulence′ and transfusion reaction with transfusion of bacterially contaminated platelets[J]. Clin Infect Dis, 2008, 46(8): 1214-1220.
[35]
Nys M,Ledous D, Canicet JL, et al. Correlation between endotoxin level and bacterial count in bronchoalveolar fluid of ventilated patients[J]. Crit Care Med, 2000, 28(8): 2825-2831.
[36]
Van Deverter SJ, Buller HR. Endotoxaemia:an early predictor of septicaemia in febrile patients[J]. Lancet, 1988, 1(8586): 605-609.
[37]
Hass A, Rossberq MI, Hooles HL, et al. Endotoxin levels in immunocompromised children with fever[J]. J Pediatr, 1986, 109(2): 265-269.
